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The ErbB receptor family are multidomain proteins that 
contain an extracellular ligand binding domain, a single 
transmembrane domain, and an intracellular tyrosine kinase 
domain.1,2 This family consists of EGFR (HER1, ErbB1), HER2 
(ErbB2, HER2/neu), HER3 (ErbB3), and HER4 (ErbB4). The 
receptors play a role in the regulation of cell proliferation, 
differentiation, and migration.3 Upon ligand binding to the 
extracellular domain, the receptors can form either homo- or 
hetero-dimers through which the cytoplasmic domains become 
catalytically active and undergo C terminus phosphorylation, 
further initiating downstream signalling events.4,5 HER2 appears 
to be the preferred binding partner of EGFR and the 
HER2/EGFR heterodimer shows an increased signalling potency 
relative to EGFR homodimers.6 HER2 itself  also undergoes 
spontaneous homo- or heterodimerization and activates 
downstream signalling.7  HER2 is overexpressed in a number of 
human cancers, including 20−40% of solid tumours including  
breast, ovarian, lung, gastric, and oral cancers where it correlates 
with poor prognosis.8-10 Given that HER2 is only expressed at 
low levels in normal human tissues, its overexpression in 
tumours makes it an attractive target for tumour-specific 
therapies.  
Two approaches have been developed for blocking the 
upregulated HER2 signal pathway. One approach utilizes the 
anti-HER2 monoclonal antibody, trastuzumab.11-13 This blocks 
the extracellular ligand-binding region of the receptor, thereby 
interfering with its activation and modulating HER2-dependent 
signalling. An alternative approach for blocking upregulated 
HER2 signal pathways involves the use of orally active small 
molecule tyrosine kinase inhibitors (TKIs) several of which have 
been developed. Among these, CP-724714has been reported as a 
HER2-specific TKI.14-15 As many types of malignancies are 
characterized by overexpression of both HER2 and EGFR, some 
interest has been focused on the development of dual inhibitors. 
Lapatinib, a dual TKI for HER2 and EGFR, was approved in 
2007 in combination with capecitabine or letrozole in patients 
with metastatic breast cancer that overexpress the HER2 
receptor.16,17 Irreversible inhibitors - Neratinib/HKI-27218,19 and 
Afatinib/BIBW-299220-21 - and reversible inhibitors - AEE-78822 
and BMS-59962623 - have also been tested in clinical trials. In 
addition to breast cancer, these HER2/EGFR dual kinase 
inhibitors are being investigated in a number of solid tumours 
including lung, gastric, and prostate cancers.16-23 
In the present study we report the computer-aided 
identification and biological evaluation of a series of novel 
compounds which binds to the kinase domains of both HER2 and 
EGFR..  
Our initial step was to perform a virtual screening against the 
two kinase domains of the target proteins (HER1 and HER2), 
using the SPECS library (~200,000 compounds).24  The three-
dimensional structures of HER2 (PDB code: 3RCD)25  and HER1 
(PDB code: 3POZ)26  used in the molecular modelling 
simulations were prepared using the protonate-3D function in 
MOE.27 The ligand library was also prepared with MOE, using 
the import conformations option, with the default settings. 
Initially, the compound library was filtered through a 
pharmacophore query, which was created by using the 
interactions of the co-crystallised ligand with the HER2 kinase 
domain (TAK-285, a dual kinase inhibitor). Filtering in this 
manner, resulted in 13017 hit structures, which were then docked 
using PLANTS.28  The results obtained, were then rescored using 
two other molecular docking software:  Glide (Standard 
Precision)29 and LeadIT.30 A simple consensus score between the 
three scoring function was then used to rank the results.31 The top 
848 compounds were then docked again using the extra precision 
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(XP) mode and the refining option in Glide.  At this point, the top 
472 structures obtained in the described simulation, were docked 
in the EGFR kinase domain structure, using the same 
docking/scoring approach described for above, but without using 
the initial pharmacophore-based filter. The docking poses of the 
top 200 structures were then visually inspected to remove all the 
poses that did not completely occupy the binding pocket of both 
structures. Finally, the 15 top-scored compounds that showed a 
consistent binding mode in the two kinases, were selected for 
biological evaluation. 
Table 1. Effects of the virtual screening hits 1 on BT474 cell 
growth at a10µM concentration. 
Compound  SPECS ID  % inhibition 
1 AJ-292/42284615 72.74±0.672 
2 AG-690/09179059 39.78±1.69 
3 AK-778/43114822 7.255±1.14 
4 AO-476/40829154 48.19±9.24 
5 AO-476/43415760 52.66±4.82 
6 AN-465/43369940 51.76±6.7 
7 AN-465/43411129 27.2±3.36 
8 AP-263/43370995 16.99±4.21 
9 AK-918/42179447 56.25±5.76 
10 AN-465/42834516 50.96±4.3 
11 AN-979/15447113 35±4.6 
12 AO-476/43380211 9.56±2.6 
13 AG-670/40909957 61.37±4.07 
14 AG-690/36158020 76.99±6.07 
15 AN-329/42285780 47.923±6.90 
Herceptin  40.19±0.86 
 
Initially, we assessed the selected molecules against the 
BT474 breast cancer cell line (Table 1), which overexpresses 
HER2 and oestrogen receptors.32 The compounds were screened 
at a 10µM concentration in a colorimetric MTT cell proliferation 
assay to assess changes in cell growth.33 All compounds were 
assessed against a control consisting of cell culture media alone 
containing the appropriate amount of drug solvent (DMSO).  
A more accurate IC50 was then calculated for the 6 compounds 
that showed the highest percentage of growth inhibition in this 
assay (Figure 1).  These compounds were also evaluated against 
the HER2+/oestrogen receptor-negative SKBR3 cell line (Table 
2). The results showed that compound 1 has best IC50 against 
SKBR3 cell line (1.03±0.413µM) whereas the best IC50 against 
BT474 was for compound 9 (0.3139 ±0.1069 µM). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of the compounds that have shown activity in the first 
assay against the BT474 cell line. 
 
Table 2. Calculated IC50 against BT474 and SKBR3 cell lines 
for selected compounds. 
Compound BT474 (µM) SKBR3 (µM) 
1 0.755±0.1126 1.03±0.413 
5 0.8023±0.145 1.64±0.062 
6 0.343±0.063 1.24±0.66 
9 0.3139±0.1069 3.11±0.415 
13 0.4261±0.083 2.26±0.672 
14 1.097±0.1684 3.17±0.470 
Herceptin 1.398±0.452 1.07±0.360 
 
To have an indication that these compounds bind to the 
intracellular kinase domains of HER1 and HER2, we performed 
an ELISA assay for both proteins.34 This specific assay indicates 
the ability of the tested compounds to inhibit the binding of an 
antibody that specifically recognises the intracellular C-terminal 
domains (the kinase domain) of the two proteins.35 This 
inhibition could occur as a direct competition effect between the 
ligand and the antibody or by the induction of a conformational 
change in the kinase domain caused by the bound ligand that 
alters the antibody recognition site. In both scenarios, the assay 
would indicate if the reported compounds bind to the kinase 
domain of the receptors. We carried out the ELISA assays on the 
6 hits (table 3). All these molecules were tested at a concentration 
of 10µM and all showed a >67% of binding inhibition. In 
particular, compound 1 showed a >80% inhibition against both 
HER1 and for HER2, with calculated IC50 of 3.92µM for HER1 
and 6.029µM for HER2. 
Table 3. ELISA assay results of selected compounds against 
HER2/HER1, as percentage of binding inhibition at 10µM 
ligand concentration 
Compound HER1 HER2 
1  83.02±3.635 85.75±0.288 
5 76.063±1.955 75.06±0.106 
6 79.89±1.053 73.14±0.123 
9 83.900± 6.5 67.04±0.13 
13 81.80± 2.8 72.10±0.3 
14 80.53± 0.7 67.09±0.116 
The proposed binding configuration of compound 1 in the 
active site of the HER2 kinase domain is shown in Figure 2. 
Compound 1 appears to form a H-bond with the Met801 NH and 
a series of hydrophobic interactions with Leu852, Leu762, 
Phe1004, Thr798, Thr862 and Leu785. The compound has also a 
very similar binding in HER1 kinase domain, forming H-bonds 
with the Met793 NH and the Lys745 side chain amino group, 
besides hydrophobic interaction with Leu718 (not shown). 
Indeed, there appeared to be some commonality in the binding 
of the 6 hit compounds (e.g. interaction with the corresponding 
Met in both HER1 and HER2) and, based on the poses obtained 
from the docking simulations, we decided to merge a set of 
structural features of the different hits in a single scaffold. In 
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particular, we designed a novel series of compound that present 
an indole ring as a simplified bicyclic heterocycle (a group 
present in all the hit structures) and a tiosemicarbazide as a 
replacement of the urea group present in 5. Furthermore, the 
tiosemicarbazide could be easily cyclised to generate an 
oxadiazole ring, which could mimic the furan ring of 14. Based 
on these concepts, we docked a series of novel structures (both 
onto HER1 and HER2) to identify the most promising 
compounds to be prepared and biologically evaluated. The 
docking results obtained for compound 16b is shown in Figure 3 
(HER1). 
 
 
 
 
 
 
 
 
 
Figure 2. Docking pose of 1 (represented in green) in the binding pocket of 
HER2. Co-crystallised ligand (TAK-285) is represented in purple. 
 
Synthesis of 17a-b was achieved by condensation of the 
commercially available indoleaceticacid hydrazide with the 
appropriate isocyante derivatives in absolute ethanol. The 
reaction produced a precipitate that was then collected and 
recrystalized from ethanol to yield 16a-b. The oxadiazole 
derivatives 17a-b were then prepared by cyclisation of 16a-b in 
presence of iodobenzoic acid in basic condition at -78ºC for 3hr 
(Scheme 1).36 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Preparation of 16a-b and 17a-b. 
The evaluation of newly synthesised compounds was carried 
initially against the SKBR3 cell line at a concentration of 10µM 
(Table 4).  
Table 4. Effects of the synthetized compounds on SKBR3 
cell growth at a10µM concentration. 
Compound % inhibition 
16a 21.245±2.21 
16b 71.51±3.32 
17a 33.36±1.32 
17b 37.17±4.10 
 
Compound 16b showed the best inhibition (71.51%) in the 
series and a more accurate biological evaluation was then 
performed resulting in a IC50 value of 0.01±0.0028µM against 
SKBR3 and 0.055±0.0212µM against BT474. A further 
evaluation was done using the ELISA assay, described above, 
against HER1 and HER2 proteins. This assay confirmed the 
binding of compound 16b to the kinase domain of HER2 (IC50 
12.37±2.50µM), and binding to HER1 (IC50 of 8.49±2.20 µM).. It 
should be noted that, for this compound, the cell-based activity is 
considerably lower than the one observed in the binding assay. 
However, as the ELISA assays provide an indication of the 
binding of the compound to the kinases, and they do not assess 
directly enzymatic inhibition, a strict correlation between the 
results of  the biochemical and cell-based anticancer assay might 
not be necessarily observed. Furthermore, at this point, we cannot 
exclude the involvement of other cellular targets beside HER1 
and HER2. 
 
 
 
 
 
 
 
 
 
Figure 3. Docking pose of 16b (represented in green) in the binding pocket 
of HER1. Co-crystallised ligand (TAK-285) is represented in purple. 
 
In conclusion, we reported the discovery, using a virtual 
screening approach, of a series of novel compounds that shows 
potent anticancer activity against both the BT747 and SKBR3 
cell lines. Furthermore, binding of these compounds to the kinase 
domains of HER1 and HER2 was assessed using an ELISA 
assay. Among these structures, compound 1 showed the lowest 
IC50 (1.03±0.413µM) against the SKBR3 cell line, . Furthermore, 
a novel series of compounds was then designed using the 
structural information of the hit molecules obtained from the in 
silico screening. These novel structures were then biologically 
evaluated and compound 16b showed nanomolar activity in both  
cell-based assays. Furthermore, the ELISA assay suggests that 
16b could target HER1 and HER2 kinase domains. However, 
further studies will be needed to confirm the mode of action for 
these compounds. We believe that both 1 and 16b represent a 
good starting point for the development of novel anticancer 
compounds, with a possible HER1/HER2 dual inhibition 
mechanism of action. 
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